Vancomycin and Breastfeeding
Yes, it is safe to breastfeed while taking vancomycin. Vancomycin is considered low risk for nursing mothers and their infants 1.
Evidence Supporting Safety
The most recent and authoritative guidance comes from the 2025 Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease, which explicitly states that "vancomycin, are also considered low risk in nursing mothers" 1. This represents the highest quality, most recent guideline evidence available.
Key Safety Points:
Minimal Breast Milk Transfer:
- Vancomycin is excreted in human milk in nonsignificant amounts 2
- The drug has low oral bioavailability, meaning even if the infant ingests vancomycin through breast milk, minimal systemic absorption occurs 2
- This pharmacokinetic profile creates a natural safety barrier for the nursing infant
Clinical Evidence:
- The FDA label confirms vancomycin is excreted in human milk but notes this as a precautionary statement rather than a contraindication 3
- A controlled clinical study evaluating vancomycin use in pregnant women found the drug in cord blood but detected no sensorineural hearing loss or nephrotoxicity attributable to vancomycin in infants 3, 4
- One infant whose mother received vancomycin in the third trimester experienced conductive hearing loss that was not attributed to vancomycin administration 3
Practical Recommendations
You can continue breastfeeding without interruption while taking vancomycin. The combination of minimal breast milk excretion and poor oral bioavailability means the infant receives negligible systemic exposure 2, 5.
Monitoring Considerations:
While vancomycin is considered safe, prudent clinical practice includes:
- No routine interruption of breastfeeding is necessary
- Monitor the infant for potential effects on gastrointestinal flora (similar to other antibiotics), such as diarrhea or candidiasis, though these are uncommon with vancomycin 1
- Be aware that the theoretical risk of altering infant gut microbiome exists with any antibiotic, but this has not been documented as clinically significant with vancomycin
Important Caveats:
The FDA label states that "caution should be exercised" and suggests considering whether to discontinue nursing or the drug based on its importance to the mother 3. However, this is standard regulatory language and does not reflect the clinical consensus that vancomycin is compatible with breastfeeding. The 2025 guideline evidence supersedes this conservative FDA language with specific low-risk designation 1.
The decision should favor continuing both vancomycin treatment and breastfeeding, as the benefits of breastfeeding combined with the minimal infant exposure make this the optimal approach for maternal infection treatment and infant health 1, 2, 5.